Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization.

Johnson JB, Lyles DS, Alexander-Miller MA, Parks GD.

J Virol. 2012 Sep;86(18):9929-40. doi: 10.1128/JVI.01154-12. Epub 2012 Jul 3.

2.

The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization.

Johnson JB, Grant K, Parks GD.

J Virol. 2009 Aug;83(15):7602-11. doi: 10.1128/JVI.00713-09. Epub 2009 May 20.

3.

Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.

Biswas M, Johnson JB, Kumar SR, Parks GD, Elankumarana S.

J Virol. 2012 Dec;86(23):12708-16. doi: 10.1128/JVI.00886-12. Epub 2012 Sep 12. Erratum in: J Virol. 2013 Jan;87(2):1287. Subbiah, Elankumaran [corrected to Elankumarana, Subbiah].

5.

Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization.

Li Y, Johnson JB, Parks GD.

Virology. 2016 Oct;497:305-313. doi: 10.1016/j.virol.2016.07.030. Epub 2016 Aug 6.

6.
7.

Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59.

Leaderer D, Cashman SM, Kumar-Singh R.

J Gene Med. 2015 Jun-Jul;17(6-7):101-15. doi: 10.1002/jgm.2829.

8.

Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.

Zell S, Geis N, Rutz R, Schultz S, Giese T, Kirschfink M.

Clin Exp Immunol. 2007 Dec;150(3):576-84. Epub 2007 Sep 28.

9.

Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus.

Ayala-Breton C, Russell LO, Russell SJ, Peng KW.

J Virol. 2014 Aug;88(15):8332-9. doi: 10.1128/JVI.03823-13. Epub 2014 May 14.

10.

Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64.

Kaname Y, Tani H, Kataoka C, Shiokawa M, Taguwa S, Abe T, Moriishi K, Kinoshita T, Matsuura Y.

J Virol. 2010 Apr;84(7):3210-9. doi: 10.1128/JVI.02519-09. Epub 2010 Jan 13.

11.

Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus.

Johnson JB, Capraro GA, Parks GD.

Virology. 2008 Jun 20;376(1):112-23. doi: 10.1016/j.virol.2008.03.022. Epub 2008 Apr 28.

12.

Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.

Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ.

Lab Invest. 1996 Jun;74(6):1039-49.

PMID:
8667608
13.
14.

Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.

Rösner T, Lohse S, Peipp M, Valerius T, Derer S.

J Immunol. 2014 Aug 1;193(3):1485-95. doi: 10.4049/jimmunol.1400329. Epub 2014 Jun 27.

15.

Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome.

Liszewski MK, Leung MK, Schraml B, Goodship TH, Atkinson JP.

Mol Immunol. 2007 Mar;44(7):1559-68. Epub 2006 Oct 5.

16.

Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.

Goslings WR, Blom DJ, de Waard-Siebinga I, van Beelen E, Claas FH, Jager MJ, Gorter A.

Invest Ophthalmol Vis Sci. 1996 Aug;37(9):1884-91.

PMID:
8759358
17.

Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.

Varsano S, Frolkis I, Rashkovsky L, Ophir D, Fishelson Z.

Am J Respir Cell Mol Biol. 1996 Dec;15(6):731-7.

PMID:
8969267
19.

High-density rafts preferentially host the complement activator measles virus F glycoprotein but not the regulators of complement activation.

Ghannam A, Hammache D, Matias C, Louwagie M, Garin J, Gerlier D.

Mol Immunol. 2008 Jun;45(11):3036-44. doi: 10.1016/j.molimm.2008.03.013. Epub 2008 May 2.

PMID:
18455798
20.

Interactions of human complement with virus particles containing the Nipah virus glycoproteins.

Johnson JB, Aguilar HC, Lee B, Parks GD.

J Virol. 2011 Jun;85(12):5940-8. doi: 10.1128/JVI.00193-11. Epub 2011 Mar 30.

Supplemental Content

Support Center